Plasma Fractionation Market| Share, Market Size and Trends 2022-2030

The Plasma Fractionation Market was valued at USD 27.40 Billion in 2021, registering a CAGR of 7.3% during the forecast period (2022-2030), the market is projected to be worth USD 51.66 Billion by 2030.

Plasma fractionation is a process by which the components of blood plasma, the liquid portion of blood, are separated and purified for medical use. Plasma is composed of water, electrolytes, enzymes, hormones, and various proteins, including antibodies and clotting factors. Plasma fractionation is used to obtain specific proteins for therapeutic use, such as in the treatment of hemophilia and other bleeding disorders, as well as to make products such as albumin and immunoglobulin.

One of the main products obtained through plasma fractionation is plasma protein therapy, which is used to treat patients with conditions such as hemophilia, von Willebrand disease, and other bleeding disorders. The clotting factors that are deficient in these patients are derived from plasma and can be obtained through fractionation and purification.

The market is projected to grow at a significant pace reaching a CAGR of approximately 7.3%, over the forecast period of 2022–2030, despite a considerable fall in product sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.

Segment:

By Product

· Albumin

· Immunoglobulins

· Coagulation factor VIII

· Coagulation factor IX

By Application

· Immunology & Neurology

· Hematology

· Critical care

· pulmonology

· Others

By End-use

· Hospitals

· Clinics

· Clinical Research Labs

· Others

Get Sample Report Here: https://marketresearchcommunity.com/sample-request/?rid=825

By Region

North America– (U.S., Canada, Mexico)

Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe)

Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific)

Latin America- (Brazil, Argentina, Chile, Rest of Latin America)

The Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA)

Key players operating in the market include CSL Limited, Grifols, S.A., Octapharma AG, Kedrion S.p.A., LFB S.A., Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., BioLife Solutions, Inc., China Biologic Products, Inc., and Biotest AG.

Overall, the plasma fractionation market Growth is expected to witness significant growth during the forecast period, due to the increasing demand for plasma-derived therapies and the development of new technologies and manufacturing techniques.

Contact:

Market Research Community

sales@marketresearchcommunity.com

Contact no.: (US) +1-214-272-039

(UK) +44-20-8133-9198